|
시장보고서
상품코드
1930060
소프트젤 캡슐 시장 : 시장 규모, 점유율 및 성장률, 산업 분석 - 유형별, 용도별, 지역별 인사이트 및 예측(2025-2034년)Softgel Capsules Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2025-2034 |
||||||
소프트젤 캡슐 시장의 성장 동인
세계 소프트젤 캡슐 시장은 2025년에 78억 7,000만 달러로 평가되었습니다. 2026년에는 83억 2,000만 달러에 달할 것으로 예측됩니다. 최종적으로 2034년까지 134억 4,000만 달러로 확대될 것으로 예상되며, 예측 기간 동안 6.18%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예측됩니다. 북미는 2025년 35.60%의 점유율로 시장을 주도할 것으로 예상되며, 임상시험 증가, 강력한 R&D 인프라, 주요 제약사의 강력한 존재감이 그 요인으로 작용할 것으로 보입니다. 미국 시장은 만성 질환에 대한 소프트젤 캡슐의 사용을 촉진하는 임상 연구 증가에 힘입어 2032년까지 39억 2,000만 달러에 달할 것으로 예측됩니다. 주요 기업으로는 제품 혁신과 시장 확대에 주력하는 캡슐사(론자), 카탈런트, 실리오 파마, 에노바 홀딩스 등이 있습니다.
소프트젤 캡슐은 젤라틴, 불투명화제, 소르비톨이나 글리세린과 같은 가소제로 포장된 반고체 또는 액체 코어를 포함하는 경구용 제형입니다. 이 캡슐은 생체이용률, 안정성, 용해도가 향상되어 의약품, 건강보조식품 및 보충제에 적합합니다. 예방 의료에 대한 인식 증가, 심혈관 질환과 같은 만성 질환의 유병률 증가, 고령화 인구 증가는 세계 소프트젤 캡슐 시장을 이끄는 주요 요인입니다.
시장 성장 촉진요인
임상시험 및 제품 출시 증가: 만성 질환 치료에서 소프트젤 캡슐을 평가하는 임상 연구 증가가 주요 성장 동인입니다. 예를 들어, 2021년 8월 InnoPharmax Inc.는 담도암 치료용 소프트젤 복합제 평가 시험을 진행했습니다. Catalent의 OptiGel DR 기술 등 주요 기업들의 제품 혁신(지연 방출형, 장용성 캡슐 구현)도 시장 확대에 힘을 보태고 있습니다.
식물성 캡슐 수요: 채식주의자 및 비건 채식주의자를 위한 소프트젤 캡슐은 천연 유래, 동물성 성분 무함유, 글루텐 프리, 유전자 변형 성분 무함유, 용해성 향상 등의 특성으로 인해 인기가 높아지고 있습니다. 특히 유럽, 북미, 아시아태평양에서는 소비자들에게 더 안전하고 효과적이라는 평가를 받고 있으며, 신제품 라인 출시와 시장 차별화의 기회를 창출하고 있습니다.
건강 및 영양 보충제 시장 성장: 2026년 건강 및 영양 보충제 부문은 57.23%의 점유율을 차지했습니다. 이는 심혈관 질환 및 노화에 따른 건강 문제를 포함한 만성질환 예방을 위한 비타민 보충제 수요 증가에 기인합니다. 또한, 만성질환의 확산과 제네릭 의약품 및 혁신적 제제의 규제 승인을 배경으로 소프트젤 형태의 처방약도 괄목할만한 성장세를 보이고 있습니다.
시장 성장 억제요인
특허만료와 제네릭 경쟁: 주요 의약품의 특허 독점권 상실은 제약기업의 수익에 부정적인 영향을 미칠 수 있으며, 제네릭 의약품과의 경쟁을 초래할 수 있습니다. 이는 시장 역학에 영향을 미치고, 자체 개발한 소프트젤 제품의 성장 가능성에도 영향을 미칠 수 있습니다.
시장 구분
유형별: 시장은 젤라틴 캡슐과 비동물성 소프트젤 캡슐로 구분됩니다. 2026년 젤라틴 캡슐은 꾸준한 R&D 투자, 높은 생산 능력, 확립된 제조 공정으로 인해 젤라틴 캡슐이 85.21%로 가장 큰 점유율을 차지했습니다. 셀룰로오스 및 풀루란 캡슐을 포함한 비동물성 부문은 비건 제품 수요 증가로 인해 꾸준히 성장하고 있습니다.
제조업체별: 제약회사가 2026년 57.04%의 점유율을 차지할 것으로 예상되며, 대규모 생산과 막대한 R&D 투자로 인해 선두를 차지할 것으로 예측됩니다. 건강기능식품 제조업체도 전 세계 건강기능식품 신제품 출시 증가를 배경으로 큰 기여를 하고 있습니다.
지역별:
- 북미: 2025년 28억 달러, 2026년 29억 7,000만 달러로 예측되며, 활발한 임상시험 활동과 FDA 승인 제품 출시에 힘입어 성장세를 보이고 있습니다.
- 아시아태평양: 환자 수 증가와 제약사의 진출로 인해 예측 기간 동안 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 2026년에는 중국이 6억 4,000만 달러, 일본이 4억 4,000만 달러, 인도가 2억 5,000만 달러에 달할 것으로 예측됩니다.
- 유럽: 젤라틴 캡슐 연구에 대한 투자와 비건 소프트젤 기술 혁신으로 견조한 성장이 예상됩니다. 2026년에는 독일이 6억 3,000만 달러, 영국이 4억 달러에 달할 것으로 예측됩니다.
- 중동 및 아프리카 및 라틴아메리카: 만성질환 유병률 증가와 영양보충제 보급 확대로 높은 성장 잠재력이 예상됩니다.
목차
제1장 서론
제2장 주요 요약
제3장 시장 역학
제4장 주요 인사이트
제5장 세계의 소프트젤 캡슐 시장 분석 : 인사이트·예측(2021-2034년)
제6장 북미 소프트젤 캡슐 시장 분석 : 인사이트와 예측(2021-2034년)
제7장 유럽 소프트젤 캡슐 시장 분석 : 인사이트와 예측(2021-2034년)
제8장 아시아태평양 소프트젤 캡슐 시장 분석 : 인사이트와 예측(2021-2034년)
제9장 라틴아메리카 소프트젤 캡슐 시장 분석 : 인사이트와 예측(2021-2034년)
제10장 중동 및 아프리카 소프트젤 캡슐 시장 분석 : 인사이트와 예측(2021-2034년)
제11장 경쟁 분석
LSH 26.02.27Growth Factors of softgel capsules Market
The global softgel capsules market was valued at USD 7.87 billion in 2025 and is projected to reach USD 8.32 billion in 2026, ultimately expanding to USD 13.44 billion by 2034, reflecting a CAGR of 6.18% during the forecast period. North America dominated the market in 2025 with a 35.60% share, driven by rising clinical trials, strong R&D infrastructure, and a high presence of key pharmaceutical manufacturers. The U.S. market is projected to reach USD 3.92 billion by 2032, supported by the growing number of clinical studies promoting the usage of softgel capsules for chronic ailments. Key players include Capsugel (Lonza), Catalent, Inc., Sirio Pharma, and Aenova Holding GmbH, focusing on product innovation and market expansion.
Softgel capsules are oral dosage forms containing a semi-solid or liquid core encapsulated within gelatin, opacifiers, and plasticizers such as sorbitol or glycerin. These capsules offer enhanced bioavailability, stability, and solubility, making them suitable for pharmaceuticals, nutraceuticals, and dietary supplements. Increasing awareness of preventive healthcare, rising prevalence of chronic diseases such as cardiovascular disorders, and a growing geriatric population are major factors driving the global softgel capsules market.
Market Drivers
Rising Clinical Trials and Product Launches: The increasing number of clinical studies evaluating softgel capsules for treating chronic diseases is a key growth driver. For example, in August 2021, InnoPharmax Inc. sponsored trials to assess softgel combinations for biliary tract cancer treatment. Product innovations by key players such as Catalent's OptiGel DR technology, enabling delayed or enteric-release capsules, further support market expansion.
Demand for Plant-Based Capsules: Vegetarian or vegan softgel capsules are gaining popularity due to their natural, non-animal composition, absence of gluten, GMO-free status, and improved solubility. These capsules are viewed as safer and more effective by consumers, particularly in Europe, North America, and Asia Pacific, creating opportunities for new product lines and market differentiation.
Health & Dietary Supplements Growth: In 2026, the health & dietary supplements segment accounted for 57.23% share, driven by the growing need for vitamins and supplements to prevent chronic diseases, including cardiovascular conditions and age-related health issues. Prescription medicines in softgel form are also witnessing significant growth, supported by chronic disease prevalence and regulatory approvals for generic and innovative formulations.
Market Restraints
Patent Expirations and Generic Competition: Loss of patent exclusivity for leading drugs may negatively impact pharmaceutical companies' revenues, introducing generic competition. This could influence market dynamics and affect growth potential for proprietary softgel products.
Market Segmentation
By Type: The market is segmented into gelatin capsules and non-animal softgel capsules. In 2026, gelatin capsules held the largest market share at 85.21%, driven by robust R&D investments, high production capacity, and established manufacturing processes. The non-animal segment, including cellulose-based and pullulan capsules, is growing steadily due to rising demand for vegan-friendly options.
By Manufacturer: Pharmaceutical companies dominate with 57.04% share in 2026, supported by large-scale production and extensive R&D investments. Nutraceutical companies also contribute significantly, benefiting from the global rise in dietary supplement launches.
By Region:
- North America: Dominated with USD 2.8 billion in 2025 and projected USD 2.97 billion in 2026, driven by strong clinical trial activity and FDA-approved product launches.
- Asia Pacific: Expected to record the highest CAGR during the forecast period due to a large patient pool and expansion of pharmaceutical companies. In 2026, China USD 0.64 billion, Japan USD 0.44 billion, and India USD 0.25 billion.
- Europe: Strong growth due to investments in gelatin capsule research and innovations in vegan softgel technologies. Germany USD 0.63 billion, UK USD 0.4 billion in 2026.
- Middle East & Africa and Latin America: High growth potential driven by rising chronic disease prevalence and increasing dietary supplement adoption.
Competitive Landscape
The global market is moderately consolidated, with Capsugel (Lonza) and Catalent, Inc. leading in revenue and product innovation. Key industry developments include the launch of Amneal Pharmaceuticals' Icosapent ethyl softgel in December 2023 and Roquette's LYCAGEL PREMIX in November 2021. Companies are focusing on expanding geographic presence, pipeline development, and advanced manufacturing technologies.
Conclusion
The global softgel capsules market is expected to grow from USD 7.87 billion in 2025 to USD 13.44 billion by 2034, driven by rising clinical trials, growing chronic disease prevalence, demand for plant-based capsules, and increasing adoption of dietary supplements. North America leads the market, while Asia Pacific is poised for the fastest growth. Gelatin capsules dominate, supported by R&D and manufacturing capacities, whereas non-animal capsules are gaining traction due to consumer preference. The market outlook remains strong as key players focus on innovation, regulatory approvals, and global expansion, ensuring sustained growth and enhanced product availability worldwide.
Segmentation By Type
- Gelatin Capsules
- Non-animal Softgel Capsules
- Starches
- Pullulan
- Others
By Application
- Prescription Medicines
- Health & Dietary Supplements
By Manufacturers
- Pharmaceutical Companies
- Nutraceutical Companies
- Others
By Region
- North America (By Type, By Application, By Manufacturers, and By Country)
- U.S.
- Canada
- Europe (By Type, By Application, By Manufacturers, and By Country/Sub-Region)
- Germany
- U.K.
- France
- Italy
- Spain
- Scandinavia
- Rest of Europe
- Asia Pacific (By Type, By Application, By Manufacturers, and By Country/Sub-Region)
- India
- China
- Japan
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Type, By Application, By Manufacturers, and By Country/Sub-Region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Type, By Application, By Manufacturers, and By Country/Sub-Region)
- GCC
- South Africa
- Rest of Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. New Product Launch, By Key Players
- 4.2. Overview of Regulatory Scenario, By Key Countries/ Regions
- 4.3. Key Industry Developments-Mergers, Acquisitions, and Partnerships
- 4.4. Impact of Covid-19 on the Market
5. Global Softgel Capsules Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Gelatin Capsules
- 5.1.2. Non-animal Softgel Capsules
- 5.1.2.1. Starches
- 5.1.2.2. Pullulan
- 5.1.2.3. Others
- 5.2. Market Analysis, Insights and Forecast - By Application
- 5.2.1. Prescription Medicines
- 5.2.2. Health & Dietary Supplements
- 5.3. Market Analysis, Insights and Forecast - By Manufacturers
- 5.3.1. Pharmaceutical Companies
- 5.3.2. Nutraceutical Companies
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast - By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Latin America
- 5.4.5. Middle East & Africa
6. North America Softgel Capsules Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Gelatin Capsules
- 6.1.2. Non-animal Softgel Capsules
- 6.1.2.1. Starches
- 6.1.2.2. Pullulan
- 6.1.2.3. Others
- 6.2. Market Analysis, Insights and Forecast - By Application
- 6.2.1. Prescription Medicines
- 6.2.2. Health & Dietary Supplements
- 6.3. Market Analysis, Insights and Forecast - By Manufacturers
- 6.3.1. Pharmaceutical Companies
- 6.3.2. Nutraceutical Companies
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast - By Country
- 6.4.1. U.S.
- 6.4.2. Canada
7. Europe Softgel Capsules Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Gelatin Capsules
- 7.1.2. Non-animal Softgel Capsules
- 7.1.2.1. Starches
- 7.1.2.2. Pullulan
- 7.1.2.3. Others
- 7.2. Market Analysis, Insights and Forecast - By Application
- 7.2.1. Prescription Medicines
- 7.2.2. Health & Dietary Supplements
- 7.3. Market Analysis, Insights and Forecast - By Manufacturers
- 7.3.1. Pharmaceutical Companies
- 7.3.2. Nutraceutical Companies
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 7.4.1. Germany
- 7.4.2. U.K.
- 7.4.3. France
- 7.4.4. Italy
- 7.4.5. Spain
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
8. Asia Pacific Softgel Capsules Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Gelatin Capsules
- 8.1.2. Non-animal Softgel Capsules
- 8.1.2.1. Starches
- 8.1.2.2. Pullulan
- 8.1.2.3. Others
- 8.2. Market Analysis, Insights and Forecast - By Application
- 8.2.1. Prescription Medicines
- 8.2.2. Health & Dietary Supplements
- 8.3. Market Analysis, Insights and Forecast - By Manufacturers
- 8.3.1. Pharmaceutical Companies
- 8.3.2. Nutraceutical Companies
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 8.4.1. India
- 8.4.2. China
- 8.4.3. Japan
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
9. Latin America Softgel Capsules Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Gelatin Capsules
- 9.1.2. Non-animal Softgel Capsules
- 9.1.2.1. Starches
- 9.1.2.2. Pullulan
- 9.1.2.3. Others
- 9.2. Market Analysis, Insights and Forecast - By Application
- 9.2.1. Prescription Medicines
- 9.2.2. Health & Dietary Supplements
- 9.3. Market Analysis, Insights and Forecast - By Manufacturers
- 9.3.1. Pharmaceutical Companies
- 9.3.2. Nutraceutical Companies
- 9.3.3. Others
- 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 9.4.1. Brazil
- 9.4.2. Mexico
- 9.4.3. Rest of Latin America
10. Middle East & Africa Softgel Capsules Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Gelatin Capsules
- 10.1.2. Non-animal Softgel Capsules
- 10.1.2.1. Starches
- 10.1.2.2. Pullulan
- 10.1.2.3. Others
- 10.2. Market Analysis, Insights and Forecast - By Application
- 10.2.1. Prescription Medicines
- 10.2.2. Health & Dietary Supplements
- 10.3. Market Analysis, Insights and Forecast - By Manufacturers
- 10.3.1. Pharmaceutical Companies
- 10.3.2. Nutraceutical Companies
- 10.3.3. Others
- 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
- 10.4.1. GCC Countries
- 10.4.2. South Africa
- 10.4.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Capsugel (Lonza)
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. financials (Based on Availability)
- 11.2.2. Sirio Pharma Co., Ltd.
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. financials (Based on Availability)
- 11.2.3. Catalent, Inc.
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. financials (Based on Availability)
- 11.2.4. Aenova Holding GmbH
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. financials (Based on Availability)
- 11.2.5. Fuji Capsule Co., Ltd.
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. financials (Based on Availability)
- 11.2.6. CAPTEK Softgel International Inc.
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. financials (Based on Availability)
- 11.2.7. Curtis Health Caps
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. financials (Based on Availability)
- 11.2.8. EuroCaps Ltd
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. financials (Based on Availability)
- 11.2.1. Capsugel (Lonza)
